MEDROXYPROGESTERONE Drug Patent Profile
✉ Email this page to a colleague
When do Medroxyprogesterone patents expire, and when can generic versions of Medroxyprogesterone launch?
Medroxyprogesterone is a drug marketed by Amneal, Amphastar Pharms Inc, Cipla, Eugia Pharma, Hikma, Hong Kong, Sandoz, Sun Pharm, Teva Pharms Usa, Xiromed, Barr, Duramed Pharms Barr, and Upsher Smith Labs. and is included in sixteen NDAs.
The generic ingredient in MEDROXYPROGESTERONE is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Medroxyprogesterone
A generic version of MEDROXYPROGESTERONE was approved as medroxyprogesterone acetate by BARR on August 9th, 1996.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MEDROXYPROGESTERONE?
- What are the global sales for MEDROXYPROGESTERONE?
- What is Average Wholesale Price for MEDROXYPROGESTERONE?
Summary for MEDROXYPROGESTERONE
| US Patents: | 0 |
| Applicants: | 13 |
| NDAs: | 16 |
| Drug Prices: | Drug price information for MEDROXYPROGESTERONE |
| Drug Sales Revenues: | Drug sales revenues for MEDROXYPROGESTERONE |
| DailyMed Link: | MEDROXYPROGESTERONE at DailyMed |
